Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
Trial details
- Registry ID
- NCT04805671
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19NCT04805671 | IVVD | Phase 2, Phase 3 | Terminated | 2022-02-10Actual |
| Evaluation of ADG20 for the Prevention of COVID-19NCT04859517 | IVVD | Phase 2, Phase 3 | Terminated | 2022-11-04Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |